SS-31 (Elamipretide) — Indexed Studies

Mitochondria dysfunction and increased expression of WNT5A and BNIP3 in tenocytes obtained from patients with tendinopathy.

Nakagawa Y, Okazaki Y, Carballo CB et al.

Real-world disease burden and health care resource utilization for patients with Barth syndrome.

Marjoram L, Huang Y, Koenig MK et al.

Patient self-selection does not influence postoperative improvements in pain, function, or satisfaction in ream-and-run arthroplasty patients.

Suttmiller AMB, Snyder BA, Carofino BC

Elamipretide in the Management of Barth Syndrome: Current Evidence and a Case Report.

Jacob N, Schecter D, Marshall M et al.

RePOWER: An International, Prospective, Non-Interventional Registry of Patients With Primary Mitochondrial Myopathy.

Karaa A, Goldstein A, Cohen BH et al.

Cardiac pathology in a patient with a novel pathogenic variant c.703del (p.Ile235SerfsTer4) of the TAFAZZIN gene.

Prasanpanich M, Husain M, Halnon NJ et al.

Initial Psychometric Evaluation of the Barth Syndrome Symptom Assessment (BTHS-SA) for Adolescents and Adults in a Phase 2 Clinical Study.

Gwaltney C, Shields A, Love E et al.

Examination of mitochondria- and inflammasome-mediated mechanisms of clozapine-induced myocarditis using patient-derived iPSC cardiomyocytes.

Vaziri N, Shutt TE, Karim W et al.

Expanded-access use of elamipretide in a newborn with Barth syndrome: a case report.

Ortmann L, Velasco D, Cole J

Expanded-access use of elamipretide in a critically ill patient with Barth syndrome.

Goldstein AC, Pantano C, Redko M et al.

Expanded-Access Use of Elamipretide Improves Quality of Life in Patients With Rare Mitochondrial Disorders Characterized by Ophthalmic Symptoms: A Case Series.

Ansari S, Koenig MK

ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation.

Ehlers JP, Hu A, Boyer D et al.

Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.

Karaa A, Bertini E, Carelli V et al.

Effect of Aficamten on Health Status Outcomes in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM.

Sherrod CF 4th, Saberi S, Nassif ME et al.

Expanded-access use of elamipretide in a patient with membrane protein-associated neurodegeneration.

Patino J, Clearman AH, Miller L et al.

Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.

Thompson WR, Manuel R, Abbruscato A et al.

Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.

Karanjia R, Sadun AA

Validation of a Reduced Set of High-Performance Triggers for Identifying Patient Safety Incidents with Harm in Primary Care: TriggerPrim Project.

Garzón González G, Alonso Safont T, Conejos Míquel D et al.

Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.

Karaa A, Bertini E, Carelli V et al.

Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.

Van den Eynde J, Chinni B, Vernon H et al.

Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases.

Koenig MK, Russo SN, McBride KL et al.

Psychometric performance of the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) in a randomized, double-blind, placebo-controlled crossover study in subjects with mitochondrial disease.

Gwaltney C, Stokes J, Aiudi A et al.

Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.

Hornby B, Thompson WR, Almuqbil M et al.

Restoring cardiolipin homeostasis mitigates cerebral ischemia-reperfusion injury by suppressing ATG5-mediated neuronal autophagy-dependent ferroptosis.

Dong W, Zhang W, Huang L et al.

Mechanisms of Anti-Oxidants, N-Acetylcysteine and Elamipretide (SS-31), on Ozone-Induced Airway Hyperresponsiveness and Mucus Hypersecretion.

Xie M, Weng J, Li C et al.

Effects of asprosin on high-fat diet-induced liver injury in rats: a histopathological, immunohistochemical, and molecular study.

Karadeniz Saygili S, Akcilar R

Association of hippocampus, entorhinal cortex, and amygdala with thyroid function: a bilateral volumetric analysis.

Hallab A, Alzheimer’s Disease Neuroimaging Initiative (ADNI)

Early targets and progressive deterioration in cardiac performance in response to chronically modified cardiac troponin I.

Ravichandran VS, Schatz TM, Lavey E et al.

Disruption of hippocampal mitochondrial function underlies opioid-induced postoperative cognitive dysfunction in aged rats.

Muscat SM, Deems NP, Alvarez BD et al.

MK-3903 alleviates myocardial ischemia/reperfusion injury and mitochondrial dysfunction associated with AMKP-PGC-1α signaling.

Li PB, Gao J, Li HH et al.

HA/CD44-SS31 Mitochondrial Targeting of Manganese Oxide Nanozymes for Ischemia-Reperfusion-Induced Acute Kidney Injury Therapy.

Lin Z, Zhou E, Zhang D et al.

The mitochondria-targeted peptide HDAP2 reduces mitochondrial loss and retinal ganglion cell degeneration after optic nerve injury.

MacNeil MA, Arain S, Mentor W et al.

SS-31 improves the quality of maternally aged oocytes by ameliorating mitochondrial function and metabolism.

Xiong D, Zhang Y, Wei J et al.

Mitochondrial Targeting by Elamipretide Improves Myocardial Bioenergetics Without Translating into Functional Benefits in HFpEF.

Schauer A, Jahn D, Vahle B et al.

Synergistic mitochondrial homeostasis regulation and cholinergic circuits reconstruction via a one-step synthesized multifunctional hydrogel facilitates spinal cord injury repair.

Luo Y, Jiang P, Huang D et al.

Targeting ANT1 to regulate PINK1/Parkin-mediated mitophagy is an effective treatment of trauma-induced tendon heterotopic ossification.

Li G, Li T, Deng Y et al.

Cuproptosis of bronchial epithelial cells triggers airway remodeling in chronic asthma.

Wang M, Liu C, Li Z et al.

Energy-replenishing, mitochondria-targeted hydrogel microspheres mitigate sarcopenia via cellular senescence amelioration.

Bao W, Liu S, Du C et al.

Elamipretide Improves Mitochondrial Function in Mitochondrial Trifunctional Protein-Deficient Mice and Human Fibroblasts.

Vieira Neto E, Wang M, Szuminsky AJ et al.

NNT inhibits microglial activation via mitochondrial oxidative stress in spinal cord injury.

Li M, Gu Q, Fan Z et al.

Mitochondria-Targeted Peptides and Bilayer Composition Modulate Membrane Electroporation under Elevated Electrochemical Stress.

Tamucci JD, Zweifach A, Alder NN et al.

Targeted Delivery of AGO-2 to Myocardial Mitochondria via Functionalized Nanoparticles Attenuates Oxidative Stress in Diabetic Cardiomyopathy.

Du W, Jiang Y, Wu L et al.

Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval.

Zhao C, Zhuang X, Gao J

Endothelial Glycocalyx Degradation as a Mediator of Neuroinflammation and Cognitive Impairment in Aged Rats: Protective Role of SS-31.

Kan MH, Liu Y, Meng FQ et al.

Effects of imeglimin on mitochondrial functions and ischemic brain damage in young and aging rats.

Paskeviciene E, Skemiene K, Pampuscenko K et al.

Mitochondrial dysfunction drives age-related degeneration of the thoracic aorta.

Dhanekula AS, Harrison BR, Pharaoh G et al.

Elamipretide Hydrochloride.

Peptide coacervate-Prussian blue hybrid supraparticle-tailored scaffolds for revitalizing diabetic heart valve regeneration via multiplex oxidative stress regulation.

Fan Y, Xingzhuang D, Zhiyu Z et al.

Potential Effect of Imeglimin on Mitochondrial Function in Subsynovial Connective Tissue of Idiopathic Carpal Tunnel Syndrome.

Ehara Y, Mifune Y, Inui A et al.

SS-31 improves post-cardiac arrest brain injury by inhibiting microglial ferroptosis and polarization.

Jiang T, Zhang H, Sun Y et al.